CD19 as a molecular target in CNS autoimmunity

Olaf Stüve, Clemens Warnke, Krystin Deason, Martin Stangel, Bernd C. Kieseier, Hans Peter Hartung, Hans Christian Von Büdingen, Diego Centonze, Thomas G. Forsthuber, Volker Knappertz

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Multiple sclerosis (MS) and neuromyelitis optica (NMO) are the most prevalent neuroinflammatory diseases of the central nervous system (CNS). The immunological cascade of these disorders is complex, and the exact spatial and temporal role of different immune cells is not fully understood. Although MS has been considered for many years to be primarily T cell driven, it is well established that B cells and the humoral immune response play an important role in its pathogenesis. This has long been evident from laboratory findings that include the presence of oligoclonal bands in the CSF. In NMO, the importance of the humoral immune system appears even more obvious as evidenced by pathogenic antibodies against aquaporin 4 (AQP4). Besides their capacity to mature into antibody-producing plasma cells, B cells are potent antigen-presenting cells to T lymphocytes and they can provide soluble factors for cell activation and differentiation to other immune-competent cells. In MS and NMO, there are substantial data from clinical trials that B cell depletion with CD20-directed agents is effective and relatively safe. Plasma cells, which produce antibodies against molecular targets expressed by the host, but which also provide humoral immune responses against pathogens, are not targeted by anti-CD20 therapies. Therefore, the depletion of CD19-expressing cells would offer potential advantages with regard to efficacy, but potentially higher risks with regard to infectious complications. This review will outline the rationale for CD19 as a molecular target in CNS autoimmunity. The current stage of drug development is illustrated. Potential safety concerns will be discussed.

Original languageEnglish (US)
Pages (from-to)177-190
Number of pages14
JournalActa Neuropathologica
Volume128
Issue number2
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'CD19 as a molecular target in CNS autoimmunity'. Together they form a unique fingerprint.

  • Cite this

    Stüve, O., Warnke, C., Deason, K., Stangel, M., Kieseier, B. C., Hartung, H. P., Von Büdingen, H. C., Centonze, D., Forsthuber, T. G., & Knappertz, V. (2014). CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica, 128(2), 177-190. https://doi.org/10.1007/s00401-014-1313-z